Andrew Goldstein, an assistant professor of UCLA Molecular, Cell and Developmental Biology and Urology, as well as a faculty member of the UCLA IUO, will be honored by the American Cancer Society with its Giants of Science Hope award. Dr. Goldstein's research focuses on developing new treatments for prostate cancer.
UCLA researcher uses big data to help optimize cancer treatment. How can datasets help reveal new ways to treat cancer? UCLA Jonsson Cancer Center's Paul Boutros shares how his lab is working in collaboration with research centers around the world to use big data to help develop new ways to fight this disease.
Story on newsroom.ucla.edu >
Dr. Brian Shuch, UCLA urologic oncologist and IUO Director of Kidney Cancer, was recently named Co-Chair of the Renal Cancer Subcommittee of the Southwest Oncology Group (SWOG). The SWOG Cancer Research Network is the oldest and largest publicly funded cancer research network. SWOG is funded by the National Cancer Institute and designs and conducts cancer medical, surgical, and radiation clinical trials. UCLA is a member of the SWOG network along with over 1000 other clinical institutions. Dr. Shuch replaces the former Co-Chair, Dr. Edward Messing, a former UCLA Urologic Oncology Fellow (1980-1982), who is the Chair Emeritus of University of Rochester. Congratulations!
Amar U. Kishan, MD, UCLA IUO researcher and radiation oncologist, was the lead author on recent study findings that were presented at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO). According to a long-term, multi-institutional study, stereotactic body radiation therapy (SBRT) is a safe and effective treatment for men with low- and intermediate-risk prostate cancer. Other UCLA IUO members were also authors on the paper. Press release >
The OLYMPUS Study - Optimized Delivery of Mitomycin for Primary UTUC Study
The purpose of this research study is to test the ability of UroGen’s MitoGel™ procedure to treat urothelial carcinoma tumors from the upper urinary tract. View Clinical Trial >
Targeted Treatment of Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to see if the study drug, Trametinib, is safe and effective for the treatment of metastatic castration-resistant prostate cancer. View Clinical Trial >
HIFU at UCLA
High-Intensity Focused Ultrasound or HIFU is an FDA-approved, minimally invasive procedure for the treatment of prostate cancer that offers personalized treatment and dramatically reduced side effects.
Learn about high intensity focused ultrasound >
View a HIFU webinar >